Varicella Virus Vaccine Live Market Report 2025 (Global Edition)

Global Varicella Virus Vaccine Live Market Report 2025 Market Size Split by Vaccine type (Monovalent Varicella Vaccine, Combination Varicella Vaccine), by End users (Hospitals, Clinic, Pharmacies, Oth...

Varicella Virus Vaccine Live Market Report Description

We have various report editions of Varicella Virus Vaccine Live Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Varicella Virus Vaccine Live Market Insights Video

Competitive Landscape of the Varicella Virus Vaccine Live Market

Market participants are working with other industry players to improve each other's research capabilities and produce new vaccines. After a successful cooperation, most organizations extend the partnership program even further. Another significant area of emphasis is the regulatory approval process. Companies are working hard to get their vaccine authorized in large markets in order to enhance their revenue stream. Acquire a tiny budding biotech firm to compete with larger market players. This expands the company's R&D portfolio and helps it prepare for forthcoming competition.

In June 2024, Sinovac Biotech Ltd reported that PROVARIX has been approved by China's National Medical Products Administration (NMPA). It is a varicella vaccination that is designed for patients above the age of 13. The two-dose schedule is planned to be included in the baseline immunization regimen. (Source: http://www.sinovac.com/en-us/news/SINOVACs-Varicella-Vaccine-was-Approved-by-China-NMPA-for-Use-in-Adolescents-and-Adults-Aged-13-Years-Old-and-Above) In October 2023, GSK plc and Chongqing Zhifei Biological Products, Ltd. have struck a three-year cooperation agreement to co-promote Shingrix (GSK's shingles vaccine) in China. (Source: https://www.pharmaceutical-technology.com/news/gsk-zhifei-shingles-vaccine-china/) In January 2022, BioNTech SE and Pfizer Inc. cooperated to develop and commercialize the first mRNA-based shingles vaccine. (Source: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-sign-new-global-collaboration-agreement)

Top Companies Market Share in Varicella Virus Vaccine Live Industry: (In no particular order of Rank)

• GlaxoSmithKline PLC
• Merck & Co. Inc.
• GC Pharma (Green Cross Holdings)
• Bio-Med Pvt Ltd
• Novo Medi Sciences Pvt Ltd
• Takeda Pharmaceutical Company Limited
• Mitsubishi Tanabe Pharma Corporation
• Sinovac Biotech Ltd.
• Changchun Keygen Biological Products Co.
• Ltd (CNBG Subsidiary)
• Sinergium Biotech
• SK Bioscience Co.
• Ltd.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Varicella Virus Vaccine Live Market

Which Region Dominates the Varicella Virus Vaccine Live Market in 2024?

According to Cognitive Market Research, North America accounted for the majority of the varicella live vaccine market in 2023 and is likely to maintain this trend due to the widespread availability of varicella live vaccinations, the presence of competent healthcare professionals, and the existence of significant key players that provide varicella live vaccines.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is predicted to develop at the quickest rate throughout the forecast period, owing to increased awareness of the value of immunization and rising disposable incomes. The expanding economies give lucrative chances for varicella live vaccination providers to grow their businesses. The continually evolving life science industry drives the growth of the market in developing countries such as India, China, Malaysia, and others.

The current report Scope analyzes Varicella Virus Vaccine Live Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Varicella Virus Vaccine Live

According to Cognitive Market Research, the global Varicella Virus Vaccine Live market size was estimated at USD 3425.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 1370.20 million in 2024 and will grow at a compound annual growth rate (CAGR) of 1.7% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Varicella Virus Vaccine Live market with a market size of USD 1081.09 million in 2024 and is projected to grow at a CAGR of 1.5% during the forecast period. The U.S. market's comprehensive vaccination programs .
• The Canada Varicella Virus Vaccine Live market had a market share of USD 164.42 million in 2024 and is projected to grow at a CAGR of 2.5% during the forecast period. Canada’s ongoing public health campaigns and collaborations
• The Mexico Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 2.2% during the forecast period, with a market size of USD 124.69 million in 2024.

Europe Varicella Virus Vaccine Live

According to Cognitive Market Research, the global Varicella Virus Vaccine Live market size was estimated at USD 3425.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 1027.65 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.0% from 2024 to 2031.

• The United Kingdom Varicella Virus Vaccine Live market had a market share of USD 172.65 million in 2024 and is projected to grow at a CAGR of 2.8% during the forecast period. In the UK, Varicella Virus Vaccine Live sales witness an upswing due to the increasing awareness of the importance of vaccinations .
• The France Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 1.2% during the forecast period, with a market size of USD 94.54 million in 2024.
• According to Cognitive Market Research, the German Varicella Virus Vaccine Live market size was valued at USD 203.47 million in 2024 and is projected to grow at a CAGR of 2.2% during the forecast period. In Germany, the Varicella Virus Vaccine Live surged due to the rise in healthcare access.
• The Italy Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 1.4% during the forecast period, with a market size of USD 88.38 million in 2024.
• The Russia Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 1.0% during the forecast period, with a market size of USD 159.29 million in 2024.
• The Spain Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 1.1% during the forecast period with a market size of USD 84.27 million in 2024
• The Luxembourg Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 2.1% during the forecast period, with a market size of USD 31.86 million in 2024.
• The Portugal Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 1.8% during the forecast period, with a market size of USD 21.58 million in 2024.
• The Greece Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 2.3% during the forecast period, with a market size of USD 12.33 million in 2024.
• The Rest of Europe's Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 0.7% during the forecast period, with a market size of USD 159.29 million in 2024.

Asia Pacific Varicella Virus Vaccine Live

According to Cognitive Market Research, the global Varicella Virus Vaccine Live market size was estimated at USD 3425.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 787.87 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.5% from 2024 to 2031.

• According to Cognitive Market Research, the China Varicella Virus Vaccine Live market size was valued at USD 354.54 million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period. Varicella Virus Vaccine Live surged in China due to strong government support for immunization programs
• The Japan Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 4.0% during the forecast period, with a market size of USD 108.73 million in 2024.
• The India Varicella Virus Vaccine Live market had a market share of USD 94.54 million in 2024 and is projected to grow at a CAGR of 7.3% during the forecast period. India's Combination of Heightened Public Awareness about Vaccination Benefits
• The South Korean Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 4.6% during the forecast period, with a market size of USD 78.79 million in 2024.
• The Australian Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 40.97 million in 2024.
• The South East Asia Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 54.36 million in 2024.
• The Rest of Asia Pacific Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 5.3% during the forecast period, with a market size of USD 55.94 million in 2024.

South America Varicella Virus Vaccine Live

According to Cognitive Market Research, the global Varicella Virus Vaccine Live market size was estimated at USD 3425.5 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 171.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.9% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Varicella Virus Vaccine Live market size was valued at USD 73.31 million in 2024 and is projected to grow at a CAGR of 3.5% during the forecast period. Varicella Virus Vaccine Lives flourished in Brazil due to growing emphasis on preventive healthcare
• Argentina's Varicella Virus Vaccine Live market had a market share of USD 28.77 million in 2024 and is projected to grow at a CAGR of 3.8% during the forecast period. Argentina's public health campaigns.
• Colombia Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 2.7% during the forecast period, with a market size of USD 15.24 million in 2024.
• Peru Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 3.1% during the forecast period, with a market size of USD 14.04 million in 2024.
• Chile Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 3.2% during the forecast period, with a market size of USD 12.33 million in 2024.
• The Rest of Latin America's Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 2.0% during the forecast period, with a market size of USD 27.58 million in 2024.

Middle East and Africa Varicella Virus Vaccine Live

According to Cognitive Market Research, the global Varicella Virus Vaccine Live market size was estimated at USD 3425.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 68.51 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031..

• The GCC Countries Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 4.0% during the forecast period, with a market size of USD 29.32 million in 2024. Varicella Virus Vaccine Live sales flourish due to the presence of major market players.
• The Egypt Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 3.5% during the forecast period, with a market size of USD 7.19 million in 2024.
• The South Africa Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 4.2% during the forecast period, with a market size of USD 10.82 million in 2024. Varicella Virus Vaccine Live sales flourished in South Africa due to increasing public awareness.
• The Turkey Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 2.7% during the forecast period, with a market size of USD 5.89 million in 2024.
• The Nigeria Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 2.3% during the forecast period, with a market size of USD 7.19 million in 2024.
• The Rest of the MEA Varicella Virus Vaccine Live market is projected to witness growth at a CAGR of 2.2% during the forecast period, with a market size of USD 8.08 million in 2024.

Varicella Virus Vaccine Live Market Analysis

Varicella Virus Vaccine Live Market Vaccine Type Segment Analysis

According to Cognitive Market Research, in 2023, the monovalent varicella vaccine segment dominated the varicella live vaccine market. Furthermore, the monovalent varicella vaccine sector is predicted to develop rapidly during the projection period, as these vaccinations are less likely to cause febrile seizures in children than combination vaccines. Furthermore, the ease of access and the presence of a large variety of products contribute to the growth of the varicella vaccine market

The combination varicella vaccine is another fast-moving segment within the Varicella Virus Vaccine Live market because it seems a convenient and efficient way of immunization. The MMRV (measles, mumps, rubella, and varicella) vaccines are examples of combination vaccines, which can give several vaccinations in one visit. In addition to saving time both for healthcare professionals and patients, increased compliance is also expected from parents and guardians because they prefer fewer visits to the clinic.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Varicella Virus Vaccine Live Industry. Request a Free Sample PDF!

Varicella Virus Vaccine Live Market End users Segment Analysis

According to Cognitive Market Research, Hospitals dominate the Varicella Virus Vaccine Live market. They tend to have the infrastructure, trained staff, and means to effectively administer vaccines; hence, they are considered the first place for most vaccinations. Also, they typically deal with larger volumes of patients, which drives their dominance in the market.

The clinics represent the fastest-growing segment. With increased focus on preventive healthcare and the convenience of local access, more patients are turning to clinics for vaccinations. In general, clinics provide a more accessible and patient-friendly environment that encourages higher vaccination rates. Their growth is fueled by their ability to offer personalized care and shorter wait times, thereby making them very attractive to families seeking varicella vaccinations.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Varicella Virus Vaccine Live Distribution channel Segment Analysis

Varicella Virus Vaccine Live Market Distribution Channel Segment Analysis

According to Cognitive Market Research, the public segment leads the pack. Public healthcare systems usually have mass vaccination programs, thus facilitating wide-scale use of vaccines. They usually draw their funding and support from the government, which ensures that there is less cost to the population while facilitating high vaccination rates

The private segment is at the highest growth pace. More and more persons are seeking personal care services and even willing to pay for the convenience for which private healthcare providers are administering varicella vaccinations. Disposable income and growing awareness related to importance in private healthcare settings fasten this rapid growth

• Public
• Private
• Others

Varicella Virus Vaccine Live Formulation Segment Analysis

Varicella Virus Vaccine Live Market Formulation Segment Analysis

According to Cognitive Market Research, In the Live market of Varicella Virus Vaccine, the single-dose vials are the most dominating ones. They are offered due to convenience, ease of use, and the presentation of one dose per vial, thus making the probability of contamination almost nil as patients get the right dose with no wastage. Such vials are also used in large quantities in clinical setups where efficiency and safety paramountly prevail

The fastest-growing segment is multi-dose vials because this product scores a higher preference owing to its cost-effectiveness and practicality in large-volume vaccination settings, where multi-dose vials allow healthcare providers to provide multiple doses from a single vial, resulting in reduced costs per dose and waste quantity. Healthcare facilities are looking for ways to optimize resources while maintaining vaccination rates-this is driving growth in this segment.

• Single-Dose Vials
• Multi-Dose Vials

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion